INHIBITION OF CONSTITUTIVE AND INDUCIBLE CYCLOOXYGENASE ACTIVITY IN HUMAN PLATELETS AND MONONUCLEAR-CELLS BY NSAIDS AND COX-2 INHIBITORS

被引:130
作者
GROSSMAN, CJ
WISEMAN, J
LUCAS, FS
TREVETHICK, MA
BIRCH, PJ
机构
[1] Molecular Science Department, Glaxo Research and Development, Ware, SG12 0DP, Hertfordshire, Park Road
[2] Pharmacology 1, Glaxo Research and Development, Ware, SG12 0DP, Hertfordshire, Park Road
关键词
HUMAN; PLATELETS; MONONUCLEAR CELLS; CYCLOOXYGENASE; NSAIDS;
D O I
10.1007/BF01782978
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
A range of NSAIDs and reported Cox 2 selective compounds were tested in human freshly isolated platelets and LPS-stimulated mononuclear cells to determine their potency and selectivity as inhibitors of constitutive (presumably Cox 1) and inducible (presumably Cox 2) cyclooxygenase respectively. All compounds tested were either equipotent at inhibiting constitutive and inducible cyclooxygenase or were selective for the inducible form. The most selective compound was Dup697 and the least selective, ketoprofen. Several compounds only produced a partial inhibition of constitutive cyclooxygenase as the maximum inhibitor concentration achievable in the assay was limited to 1 mM. With the exception of paracetamol, all compounds were able to produce full inhibition curves against the inducible form. Potency estimates against constitutive Cox compare closely with published data but most compounds were consistently more potent against the inducible isoform than in published data for human cloned, microsomal Cox 2. These data suggest that human mononuclear cells are either exquisitely sensitive to some NSAIDs or they may contain another Cox isoform as yet indistinguishable from Cox 2.
引用
收藏
页码:253 / 257
页数:5
相关论文
共 23 条
  • [1] GASTROINTESTINAL DAMAGE ASSOCIATED WITH THE USE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS
    ALLISON, MC
    HOWATSON, AG
    TORRANCE, CJ
    LEE, FD
    RUSSELL, RI
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (11) : 749 - 754
  • [2] ASLANIAN R, 1994, EXPERT OPIN INV DRUG, V3, P1323
  • [3] PURIFICATION, CHARACTERIZATION AND SELECTIVE-INHIBITION OF HUMAN PROSTAGLANDIN-G/H SYNTHASE-1 AND SYNTHASE-2 EXPRESSED IN THE BACULOVIRUS SYSTEM
    BARNETT, J
    CHOW, J
    IVES, D
    CHIOU, M
    MACKENZIE, R
    OSEN, E
    NGUYEN, B
    TSING, S
    BACH, C
    FREIRE, J
    CHAN, H
    SIGAL, E
    RAMESHA, C
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 1994, 1209 (01): : 130 - 139
  • [4] BATTISTINI B, 1994, DRUG NEWS PERSPECT, V7, P501
  • [5] NABUMETONE (BRL14777,4-[6-METHOXY-2-NAPHTHYL]-BUTAN-2-ONE) - A NEW ANTI-INFLAMMATORY AGENT
    BOYLE, EA
    FREEMAN, PC
    MANGAN, FR
    THOMSON, MJ
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 1982, 34 (09) : 562 - 569
  • [6] BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
  • [7] CREMINON C, 1994, 9TH INT C PROST REL
  • [8] HUMAN PLATELET ERYTHROLEUKEMIA CELL PROSTAGLANDIN G/H SYNTHASE - CDNA CLONING, EXPRESSION, AND GENE CHROMOSOMAL ASSIGNMENT
    FUNK, CD
    FUNK, LB
    KENNEDY, ME
    PONG, AS
    FITZGERALD, GA
    [J]. FASEB JOURNAL, 1991, 5 (09) : 2304 - 2312
  • [9] NS-398, A NEW ANTIINFLAMMATORY AGENT, SELECTIVELY INHIBITS PROSTAGLANDIN-G/H SYNTHASE CYCLOOXYGENASE (COX-2) ACTIVITY IN-VITRO
    FUTAKI, N
    TAKAHASHI, S
    YOKOYAMA, M
    ARAI, I
    HIGUCHI, S
    OTOMO, S
    [J]. PROSTAGLANDINS, 1994, 47 (01): : 55 - 59
  • [10] GANS KR, 1990, J PHARMACOL EXP THER, V254, P180